VTRO (Vitro Biopharma) Change In Receivables: $0.04 Mil (TTM As of Oct. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vitro Biopharma Change In Receivables?

Vitro Biopharma VTRO Change In Receivables is $0.04 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's change in receivables for the quarter that ended in Oct. 2022 was $0.04 Mil. It means Vitro Biopharma's Accounts Receivable declined by $0.04 Mil from Oct. 2021 to Oct. 2022 .

Vitro Biopharma's change in receivables for the fiscal year that ended in Oct. 2022 was $0.04 Mil. It means Vitro Biopharma's Accounts Receivable declined by $0.04 Mil from Oct. 2021 to Oct. 2022 .

Vitro Biopharma's Accounts Receivable for the quarter that ended in Oct. 2022 was $0.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vitro Biopharma's Days Sales Outstanding for the three months ended in Oct. 2022 was 2.05.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vitro Biopharma's liquidation value for the three months ended in Oct. 2022 was $-4.80 Mil.

Vitro Biopharma  (AMEX:VTRO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vitro Biopharma's Days Sales Outstanding for the quarter that ended in Oct. 2022 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.074/3.293*91
=2.05

2. In Ben Graham's calculation of liquidation value, Vitro Biopharma's accounts receivable are only considered to be worth 75% of book value:

Vitro Biopharma's liquidation value for the quarter that ended in Oct. 2022 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.742-5.738+0.75 * 0.074+0.5 * 0.28
=-4.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Change In Receivables Related Terms

Vitro Biopharma Change In Receivables Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Change In Receivables Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.01 0.00 0.02 0.04

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 0.00 0.02 0.04

Vitro Biopharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Oct. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.04 Mil mean?
Vitro Biopharma (VTRO) has a Change In Receivables of $0.04 Mil as of Oct. 2022. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Vitro Biopharma and its competitors.
Is Vitro Biopharma's Change In Receivables too high?
Vitro Biopharma's current Change In Receivables is $0.04 Mil.
How does Vitro Biopharma's Change In Receivables compare to ?
Vitro Biopharma's Change In Receivables of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Vitro Biopharma and its competitors. Vitro Biopharma's current Change In Receivables is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Change In Receivables of $0.04 Mil. The current Change In Receivables is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Change In Receivables is $0.04 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.